Subscribe to our Newsletters !!

    Research

    Drug discovery pipeline to exploit transcription factors for cancer therapy

    Cancer is a major cause of death and among the most complicated challenges to contemporary medication. By employing cutting-edge technologies that precisely measure the effects of candidate targets and drugs on the fundamental process of transcription, the new start-up firm QUANTRO Therapeutics tries to radically change the precision and range of cell-based drug screening. QUANTRO’s

    Test mRNA-based COVID-19 immunization evokes defensive safe reactions in animals

    Two injections of this vaccine were enough to induce robust immunity, completely preventing SARS-CoV-2 infection in mice. MRNA-based vaccines are all attractive options for protecting against SARS-CoV-2 because they may be quickly designed and manufactured at a huge scale within weeks. Moreover, preclinical studies have shown that mRNA-based vaccines cause potent and broadly protective immune

    Analysts recognize anticoagulation operator that stifles SARS-CoV-2 replication in vitro

    Effective antivirals with secure clinical profile are urgently needed to improve the overall prognosis. In an analysis of a randomly collected cohort of 124 patients using COVID-19, the authors discovered that hypercoagulability according to elevated levels of D-dimers was associated with illness severity. By calculating of a U.S. FDA approved drug library, the authors identified

    Nitric oxide treatment can be essential in the battle against COVID-19

    Nitric oxide therapy could be critical in the world’s struggle against SARS-CoV-2, the coronavirus which causes COVID-19, according to a review by the George Washington University (GW). Nitric oxide is an antimicrobial and anti inflammatory molecule with key roles in pulmonary arterial role in the context of viral infections as well as other pulmonary diseases.

    Waterloo Technology profiles Compounds in blood of COVID-19 Sufferers

    A world-leading University of Waterloo spinoff company, that decodes blood samples for potential treatments for illnesses such as cancer and COVID-19, is expanding operations with the support of a 5-million USD investment. Bin Ma, a University of Waterloo computer engineering professor who co-founded Rapid Novor at 2015, says that the company’s technologies is the most

    Harbour BioMed and Viva Biotech declare key coordinated effort to promote biotech new startups

    HBM will combine its top Harbour Mice® stage H2L2 and its expertise in global research and development of innovative molecules, with Viva Biotech’s structure-based early phase drug discovery services. This complementary partnership will provide advanced biotech startups access to next generation technologies that create synergies to accelerate the route between ideation to merchandise. The incubated

    FDA authorizes initial two COVID-19 serology tests

    Today, the U.S. Food and Drug Administration approved the initial two COVID-19 serology tests which show an estimated amount of antibodies within somebody’s blood. Both tests from Siemens, the ADVIA Centaur COV2G and Attelica COV2G are what are known as”semi-quantitative” evaluations, meaning that they don’t show an exact measurement, but estimate the number of a